OverviewSuggest Edit

Circassia is a world-class specialty biopharmaceutical business focused on allergy and respiratory disease. The Company has an established commercial infrastructure, marketed products, a pipeline of near-term therapies and a portfolio of next generation treatments targeting multi-$billion market opportunities. Circassia sells its novel, market-leading products for asthma management directly to allergy / asthma specialists in the United States and Germany. Its products are also promoted in a number of other countries by the Company’s international network of partners.
Circassia’s broad-based development pipeline includes a range of treatments for allergy and respiratory disease. Circassia’s most advanced next-generation immunotherapy is currently in phase III testing for cat allergy, and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia’s lead asthma product targets substitution of GSK’s FLIXOTIDE® pMDI, and UK approval is expected in December 2015. Circassia anticipates two further product filings in 2016, targeting direct substitution of SERETIDE® pMDI and SEREVENT® pMDI. The Company is also developing a number of novel treatments, including a fixed dose ‘triple’ combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

TypePublic
Founded2006
HQOxford, GB
Websitecircassia.com
Employee Ratings2.5

Latest Updates

Employees (est.) (Feb 2019)400
Job Openings52
Revenue (FY, 2016)£17 K

Key People/Management at Circassia

Steve Harris

Steve Harris

CEO
Julien Cotta

Julien Cotta

CFO
Rod Hafner

Rod Hafner

Senior Vice President Research & Development
David L Acheson

David L Acheson

Senior Vice President US Commercial
Darren Mercer

Darren Mercer

Senior Vice President EU & RoW Commercial
Nina Kataria

Nina Kataria

Senior Vice President Global Human Resources
Show more

Circassia Office Locations

Circassia has offices in Oxford, Chicago and Solna
Oxford, GB (HQ)
The Oxford Science Park
Solna, SE
18 Råsundavägen
Chicago, US
101 N Upper Wacker Dr #100
Show all (3)
Report incorrect company information

Circassia Financials and Metrics

Circassia Revenue

Circassia's revenue was reported to be £17 k in FY, 2016
GBP

Revenue (FY, 2016)

17.0k

Net income (FY, 2016)

17.0k

EBITDA (FY, 2016)

17.0k

EBIT (FY, 2016)

17.0k
GBPFY, 2008FY, 2009FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

17.0k

EBITDA

(624.7k)(362.3k)(188.0k)(3.0k)17.0k

EBITDA margin, %

100%

EBIT

(624.7k)(362.3k)(295.0k)(3.0k)17.0k
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Accounts Receivable

1.017.2k104.4k27.0k1.0k

Current Assets

19.6k1.01.017.2k104.4k27.0k1.0k

Total Assets

19.6k1.0106.8k124.0k211.2k27.0k1.0k

Accounts Payable

190.5k34.6k84.7k154.3k21.0k
GBPFY, 2008FY, 2009FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(624.7k)(362.3k)(269.0k)(2.0k)(1.0k)17.0k

Income Taxes Paid

26.0k1.0k(1.0k)
Show all financial metrics
Report incorrect company information

Circassia News and Updates

Remembering when European migrants once flocked to North African shores

“Praise be to God. To my master, may god preserve you. After our master scolded me and became angry with me, accusing me of having…

Allergy Treatment Global Market 2018: Key Players – ALK, Stallergenes Greer, Allergy Therapeutics, HAL Allergy Group, Circassia

Allergy Treatment -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

World Allergy Immunotherapy Market is Estimated to Reach USD 4,324.7 million by 2023

Market Research Future published a cooked research report on “Global Allergy Immunotherapy Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Circassia Blogs

Circassia Announces Successful Completion of FDA Pre-submission Meeting for Novel Nitric Oxide Product AirNOvent

Click here to download the full press release Oxford, UK – 4 February 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces its partner,...

Circassia to Acquire US and Chinese Commercialisation Rights to Novel Nitric Oxide Product AirNOvent from AIT Therapeutics Inc.

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014 Click here to download the full press release Oxford, UK – 24 January 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”;...

Circassia to Exercise Option for Full US Commercial Rights to COPD Treatment Tudorza® from AstraZeneca

Click here to download the full press release Oxford, UK – 11 December 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces it has...

Circassia Announces Duaklir® New Drug Application (NDA) and Tudorza® Supplemental NDA Accepted for Review by FDA

Click here to download full press release – PDUFA target action date of 31 March 2019 confirmed for both filings – Oxford, UK – 13 August 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR),...

Circassia Frequently Asked Questions

  • When was Circassia founded?

    Circassia was founded in 2006.

  • Who are Circassia key executives?

    Circassia's key executives are Steve Harris, Julien Cotta and Rod Hafner.

  • How many employees does Circassia have?

    Circassia has 400 employees.

  • What is Circassia revenue?

    Latest Circassia annual revenue is £17 k.

  • What is Circassia revenue per employee?

    Latest Circassia revenue per employee is £43 .

  • Who are Circassia competitors?

    Competitors of Circassia include Durect, Amarin and Array BioPharma.

  • Where is Circassia headquarters?

    Circassia headquarters is located at The Oxford Science Park, Oxford.

  • Where are Circassia offices?

    Circassia has offices in Oxford, Chicago and Solna.

  • How many offices does Circassia have?

    Circassia has 3 offices.